FY2025 · ended Dec 31, 2025 · Revenue $225.21M, +20.2% YoY · Filed Feb 24, 2026
Axogen, Inc. (AXGN) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $225.2 million and a net loss of $15.7 million. Free cash flow was -$2.9 million. As of Sep 30, 2026 it held $348.1 million in cash and investments and $19.5 million in total debt.
Revenue (TTM)
$266.93M
+24.3% vs year-ago TTM
Net income (TTM)
$-31.92M
-1422.3% vs year-ago TTM
Operating cash flow (TTM)
$28.36M
+335.7% vs year-ago TTM
Free cash flow (TTM)
$22.04M
+559.7% vs year-ago TTM
EPS (TTM)
$-0.62
-1254.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
51.90M
+17.0% vs prior year
Net cash
$328.60M
as of Sep 30, 2026
Operating margin
-5.2%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- AXGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MN
- Headquarters
- Alachua, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 805928
- Former names
- LECTEC CORP /MN/ (until Sep 29, 2011)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
- CapsoVision, Inc CV
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $225.2M | $187.3M | $159.0M | $138.6M | $127.4M |
| Operating income | -$7.8M | -$3.3M | -$21.5M | -$29.7M | -$25.4M |
| Net income | -$15.7M | -$10.0M | -$21.7M | -$28.9M | -$27.0M |
| Diluted EPS | -$0.34 | -$0.23 | -$0.51 | -$0.69 | -$0.65 |
| Operating cash flow | $812,000 | $4.5M | -$5.7M | -$16.1M | -$13.4M |
| Free cash flow | -$2.9M | $1.4M | -$19.6M | -$36.1M | -$41.2M |
| Total assets | $221.7M | $203.7M | $196.8M | $195.4M | $208.0M |
| Total liabilities | $92.8M | $99.8M | $101.2M | $94.4M | $95.5M |
| Stockholders' equity | $128.8M | $103.9M | $95.7M | $101.0M | $112.5M |
| Cash and investments | $41.5M | $33.5M | $31.0M | $48.8M | $84.1M |
| Total debt | $67.6M | $68.7M | $69.3M | $67.4M | $67.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K/A |
Amended current report
Material agreement, Regulation FD disclosure
|
Sep 10, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
All 1000 Axogen, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.